# Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents

**LENGTH OF AUTHORIZATIONS**: 365 Days

Short Acting products considered separately from Long-Acting products

**PRIOR AUTHORIZATION CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval?

    Acceptable reasons include:

    - Allergy to at least **two** medications not requiring prior approval

    - Contraindication to all medications not requiring prior approval

    - History of unacceptable/toxic side effects to at least **two** medications not requiring prior approval

    - Has the patient failed a therapeutic trial of at least **14 days** with at least **two** medications not requiring prior approval?

**STEP THERAPY:**

1. For a drug requiring step therapy, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days** of at least 8*two preferred** products.

Note: Patients on non-preferred therapies are not required to obtain prior authorization for the use of their product until after June 30th, 2022. Providers may obtain prior authorization before June 30th, 2022.

AR - Dextroamphetamine Solution: a PA is required for patients over 12 years old AR - Methylphenidate Solution: a PA is required for patients over 12 years old
